NCT06300580

Study of Oral ABBV-932 Capsules to Evaluate Dopamine D2 and D3 Receptor Occupancy in Brain in Adult Healthy Volunteers

An Open-Label Positron Emission Tomography (PET) Study to Evaluate the Dopamine D2 and D3 Receptor Occupancy in the Brain After Multiple Doses of ABBV-932

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 23 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objective of this study is to evaluate the dopamine D2 and D3 receptor occupancy in the brain as measured by PET with radiotracer \[11C\]-(+)-PHNO up to 14 days of once-daily oral doses of ABBV-932 in healthy subjects. ABBV-932 is a dopamine D3 receptor-preferring D3/D2 receptor partial agonist. Approximately 12 adult healthy volunteers will be enrolled in the United Kingdom. Participants will receive ABBV-932 oral capsules once daily for 2 weeks and followed for 60 days. Participants will be confined for approximately 15 days. Participants will receive 3 \[11C\]-(+)-PHNO PET scans during the study. Adverse Events and blood tests will be performed.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ABBV-932	Oral Capsule

Timeline

• Start date: 2024-08-21
• Primary completion: 2025-05-26
• Completion: 2025-05-26
• First posted: 2024-03-08
• Last updated: 2025-06-05

Locations

1 site across 1 country: United Kingdom